Optimizing Imaging in ER-positive Metastatic Breast Cancer to Improve Clinical Outcomes
December 22nd 2021Gary Ulaner, MD, PhD and Jeremy Force, DO discuss the role of various strategies to detect estrogen receptor (ER)-positive breast cancer, with particular focus on the role of 18F-FES-PET imaging in diagnosis and treatment of ER-positive breast cancer and in improving patient outcomes.
Experts Share Insights on NCCN Guidelines for Metastatic TNBC
December 17th 2021As part of its Speaking Out video series, CURE spoke with Rebecca Moroose, MD, from Orlando Health Cancer Institute, and Virginia G. Kaklamani, MD, from UT Health San Antonio, about the National Comprehensive Cancer Network guidelines and what they mean for patients.
OncLive News Network: On Location at ASH 2021
December 11th 2021Join us LIVE at this year's 2021 ASH Annual Meeting! OncLive® will broadcast a series of interviews with top thought leaders across hematologic malignancies. The experts will share their insights and reactions to the pivotal data presented during the conference.
Antibody-Drug Conjugates in NSCLC: Update on TROPION-PanTumor01 Data
October 22nd 2021Rebecca Suk Heist, MD, MPH, and Solange Peters, MD, PhD, discuss data updates from the TROPION-PanTumor01 study that impact the use of antibody-drug conjugates as a therapy option for patients with second-line metastatic non-small cell lung cancer.
Screening and Treatment for Lung Cancer: What's Next?
October 13th 2021The second part of the webinar Lung Cancer Screening and Treatment: What's Next? focuses on the review of lung cancer screening and treatment status amid the COVID-19 pandemic. Participating faculty include Albert Rizzo, MD, FCCP, FACP, FAASM; James L. Mulshine, MD; Andrea Borondy Kitts, MS, MPH; and Sandip Patel, MD.
Tucatinib in Combination with Trastuzumab and Capecitabine in HER2-Positive Metastatic Breast Cancer
July 15th 2021Sara A. Hurvitz, MD, discusses updated results of the HER2CLIMB trial of tucatinib in combination with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer.
Post-Conference Perspectives: Hormone Receptor-Positive Advanced Breast Cancer
July 9th 2021Nicholas McAndrew, MD, MSCE provides his perspective on how findings reported at ASCO 2021 will impact treatment of patients with PIK3CA-mutated HR+, HER2- advanced breast cancer. In this series, Dr. McAndrew reviews the overall survival results from MONALEESA-3, the joint analysis of SOLAR-1 and X2101, the design and outcomes of the BYLieve trial, and real-world clinical outcomes using alpelisib in patients with PIK3CA-mutated HR+, HER2- advanced breast cancer.